CN102395371A - 用于治疗认知障碍的5-ht4受体促效剂化合物 - Google Patents

用于治疗认知障碍的5-ht4受体促效剂化合物 Download PDF

Info

Publication number
CN102395371A
CN102395371A CN2010800164976A CN201080016497A CN102395371A CN 102395371 A CN102395371 A CN 102395371A CN 2010800164976 A CN2010800164976 A CN 2010800164976A CN 201080016497 A CN201080016497 A CN 201080016497A CN 102395371 A CN102395371 A CN 102395371A
Authority
CN
China
Prior art keywords
methyl
compound
amino
isopropyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800164976A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·贝亚蒂耶
沈菲
杰奎琳·A·M·史密斯
罗伯特·默里·麦金内尔
蕾·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Priority to CN201610257689.5A priority Critical patent/CN105832735A/zh
Publication of CN102395371A publication Critical patent/CN102395371A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800164976A 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物 Pending CN102395371A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610257689.5A CN105832735A (zh) 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US61/168,741 2009-04-13
US29255910P 2010-01-06 2010-01-06
US61/292,559 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610257689.5A Division CN105832735A (zh) 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物

Publications (1)

Publication Number Publication Date
CN102395371A true CN102395371A (zh) 2012-03-28

Family

ID=42237213

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800164976A Pending CN102395371A (zh) 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物
CN201610257689.5A Pending CN105832735A (zh) 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610257689.5A Pending CN105832735A (zh) 2009-04-13 2010-04-12 用于治疗认知障碍的5-ht4受体促效剂化合物

Country Status (24)

Country Link
US (2) US8404711B2 (https=)
EP (1) EP2419104B1 (https=)
JP (1) JP2012523437A (https=)
KR (1) KR20120017421A (https=)
CN (2) CN102395371A (https=)
AU (1) AU2010236734B2 (https=)
BR (1) BRPI1013777A8 (https=)
CA (1) CA2758321A1 (https=)
CY (1) CY1119800T1 (https=)
DK (1) DK2419104T3 (https=)
ES (1) ES2654930T3 (https=)
HR (1) HRP20180018T1 (https=)
HU (1) HUE038141T2 (https=)
IL (1) IL215660A0 (https=)
LT (1) LT2419104T (https=)
MX (1) MX2011010782A (https=)
NO (1) NO2419104T3 (https=)
PL (1) PL2419104T3 (https=)
PT (1) PT2419104T (https=)
RU (1) RU2569056C2 (https=)
SI (1) SI2419104T1 (https=)
SM (1) SMT201800036T1 (https=)
WO (1) WO2010120695A2 (https=)
ZA (1) ZA201107490B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996961A (zh) * 2017-07-31 2020-04-10 施万生物制药研发Ip有限责任公司 利用维司曲格治疗胃轻瘫症状的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
JP6009080B2 (ja) 2012-08-16 2016-10-19 ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 老化及び認知症の予防及び／または治療活性を有する乳酸菌
BR112019001145A2 (pt) 2017-05-24 2019-04-30 H. Lundbeck A/S combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151264A (zh) * 2005-04-06 2008-03-26 施万制药 喹啉酮甲酰胺化合物的结晶形式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133078A1 (en) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151264A (zh) * 2005-04-06 2008-03-26 施万制药 喹啉酮甲酰胺化合物的结晶形式

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郭盈杉等: "抗老年痴呆药－乙酰胆碱酶抑制剂进展", 《河北化工》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996961A (zh) * 2017-07-31 2020-04-10 施万生物制药研发Ip有限责任公司 利用维司曲格治疗胃轻瘫症状的方法

Also Published As

Publication number Publication date
PT2419104T (pt) 2018-01-31
RU2011146032A (ru) 2013-05-20
KR20120017421A (ko) 2012-02-28
EP2419104B1 (en) 2017-11-08
IL215660A0 (en) 2012-01-31
WO2010120695A3 (en) 2010-12-02
JP2012523437A (ja) 2012-10-04
US20140057939A1 (en) 2014-02-27
DK2419104T3 (en) 2018-02-05
BRPI1013777A8 (pt) 2017-09-19
US20100261752A1 (en) 2010-10-14
CA2758321A1 (en) 2010-10-21
SI2419104T1 (en) 2018-03-30
AU2010236734A8 (en) 2012-02-16
NO2419104T3 (https=) 2018-04-07
CN105832735A (zh) 2016-08-10
US8404711B2 (en) 2013-03-26
MX2011010782A (es) 2012-01-20
ES2654930T3 (es) 2018-02-15
LT2419104T (lt) 2018-02-12
WO2010120695A2 (en) 2010-10-21
ZA201107490B (en) 2012-06-27
HRP20180018T1 (hr) 2018-02-09
RU2569056C2 (ru) 2015-11-20
SMT201800036T1 (it) 2018-03-08
BRPI1013777A2 (pt) 2016-04-05
AU2010236734B2 (en) 2015-06-11
AU2010236734A1 (en) 2011-11-03
PL2419104T3 (pl) 2018-04-30
EP2419104A2 (en) 2012-02-22
HUE038141T2 (hu) 2018-10-29
CY1119800T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
CN102395371A (zh) 用于治疗认知障碍的5-ht4受体促效剂化合物
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
KR102559354B1 (ko) 치매 치료
US11564888B2 (en) Extended release compositions comprising trihexyphenidyl
TWI549678B (zh) ４－胺基吡啶於改善具有脫髓鞘及其他神經系統狀況之患者的神經認知及／或神經精神缺陷之用途
WO2013024164A1 (en) Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
TW200803851A (en) Pharmaceutical composition for improvement of cognitive function
CA2898045C (en) Use of alpha 7 nicotinic acetylcholine receptor agonists
CN102753171A (zh) 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
CN105263492B (zh) α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
CN112703000A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
JP2009520726A (ja) ５−ｈｔ４アゴニストおよびコリンエステラーゼ阻害剤の組合せ剤
CN112672743A (zh) 肝病瘙痒症状的治疗
TW200848041A (en) A medicament for treating schizophrenia comprising cilostazol
HK1165722B (en) Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders
JP2023544224A (ja) ヒト低コリン作動性障害の処置のための医薬の組合せ
HK40045293A (en) Treatment of chronic cough, breathlessness and dyspnea
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHWAN BIOPHARMA RESEARCH + DEVELOPMENT IP CO., LT

Free format text: FORMER OWNER: SCHWAN PHARMACY

Effective date: 20140909

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140909

Address after: American California

Applicant after: THERAVANCE BIOPHARMA R.D IP, LLC

Address before: American California

Applicant before: Shiwan Pharmaceuticals Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120328